June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
DEMOGRAPHICS AND CLINICAL FEATURES IN SERPIGINOUS CHOROIDOPATHY AND ACUTE MULTIFOCAL PLACOID PIGMENTED EPITHELIOPATHY (AMPPE)
Author Affiliations & Notes
  • Ester Carreno
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Dawn Sim
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
    National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Pearse Keane
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
    National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
  • Javier Zarranz-Ventura
    National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, United Kingdom
    Vitreo-Retinal Service, Gloucestershire NHS Foundation Trust, Cheltenham, United Kingdom
  • Guillermo Fernandez Sanz
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Dhanes Thomas
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Mark Westcott
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Adnan Tufail
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Carlos Pavesio
    Medical Retina, Moorfields Eye Hospital, London, United Kingdom
  • Footnotes
    Commercial Relationships Ester Carreno, None; Dawn Sim, None; Pearse Keane, None; Javier Zarranz-Ventura, None; Guillermo Fernandez Sanz, None; Dhanes Thomas, None; Mark Westcott, None; Adnan Tufail, Allergan (C), Bayer (C), GSK (C), Oculogics (C), Pfizer (C), Thrombogenics (C), Amakem (C), Heidelberg Engineering (R), Novarits/Alcon (C), Sanofi/Genzyme (C); Carlos Pavesio, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 2944. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Ester Carreno, Dawn Sim, Pearse Keane, Javier Zarranz-Ventura, Guillermo Fernandez Sanz, Dhanes Thomas, Mark Westcott, Adnan Tufail, Carlos Pavesio; DEMOGRAPHICS AND CLINICAL FEATURES IN SERPIGINOUS CHOROIDOPATHY AND ACUTE MULTIFOCAL PLACOID PIGMENTED EPITHELIOPATHY (AMPPE). Invest. Ophthalmol. Vis. Sci. 2013;54(15):2944.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To describe the clinical features and outcomes of a large group of patients with a spectrum of clinical appearances and diagnosed as having Serpiginous Choroidopathy (SC) or Acute Multifocal Placoid Pigmented Epitheliopathy (AMPPE).

Methods: In a retrospective consecutive case series, patients seen during a 12-year period at Moorfields Eye Hospital who were diagnosed as having SC or AMPPE were included. Main outcome measures included initial and final visual acuity, laterality, sparing of the peripapillary area, development of choroidal neovascularization (CNV), number of flare ups during follow up. Statistical significance for intergroup differences was assessed by Mann-Whitney’s U test and Fisher’s test.

Results: A total of 43 patients (86 eyes), 16 (32 eyes) with serpiginous choroidopathy and 27 (54 eyes) with AMPPE were included. The average age was 37.7 years; 49.3 years in the SC group, and 30.9 in the AMPPE group (p=0.001). 24/43 patients (55.8%) were male; 7/16 (46.67%) males in the SC group and 17/27 (60.71%) males in the AMPPE group (p=0.341). The overall mean follow-up was 3.79 years. Thirty-two patients had bilateral disease, 13 bilateral SC, 19 bilateral AMPPE (p=0.494). Mean initial visual acuity 20/30 in all patients (20/40 SC, 20/25 AMPPE) (p=0.003). The mean final visual acuity was 20/25 (20/40 SC, 20/20 AMPPE) (p=0.000). 4 patients with SC, compared to non with AMPPE developed CNV (4.7%) (p=0.017). The mean number of flare ups during the follow up period was 0.67 in all patients, 0.88 for SC, and 0.55 for AMPPE (p=0.003).

Conclusions: A large group of patients with serpiginous choroidopathy and AMPPE were reviewed. Different clinical findings and visual outcomes were found between both groups. AMPPE has a better visual outcome, affecting younger patients, less flare ups during the follow-up and lack of associated CNV. These finding suggest a different underlying etiopathology for SC and AMPPE.

Keywords: 452 choroid • 557 inflammation • 688 retina  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×